Shokouhifar et al. found that the differentiation of ex vivo expanded CD34+ cells through manipulation of RAS/MAPK, IGF-1R, and TGF-β signaling pathways is an efficient approach for generating functional NK cells that can be used for cancer immunotherapy [83]. The gene discussed is CD34; the disease is cancer.